Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

Abstract

3 on behalf of the SA.FE. study group

Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

“…After removal of duplicates and publications that did not meet the inclusion criteria, a total of 10 articles were included (Figure 1). The studies were conducted between 2012 and 2020 and majority of them were from UK [15][16][17][18][19] , USA 10,11 or Italy 20,21 . Characteristics of included studies are presented in Table 1 and 2.…”

“…Characteristics of included studies are presented in Table 1 and 2. Multiple sclerosis (MS) associated spasticity was the most common disease state for which cost-effectiveness of medicinal cannabis were evaluated (n=7) [15][16][17][19][20][21][22][23] . The remaining studies were conducted in patients with pediatric drug-resistant epilepsies (Dravet syndrome -DS 9 and Lennox-Gastaut Syndrome -LGS 10 ) and chronic pain 11,18 .…”

“…All studies applied cost-utility analysis (CUA), with majority of studies (n=10) being CUAs based on a Markov model [9][10][11][16][17][18][19][21][22][23] . The remaining studies were CUAs conducted alongside a clinical trial 15 or based on real world patient-level data from a national registry 20 . All included studies were analysed using a healthcare payer perspective.…”

“…All included studies were analysed using a healthcare payer perspective. All except one studies included 'standard of care (SoC)' in both intervention and comparator arms while the Mantovani et al 2020 study 20 compared Cannabinoid Oromucosal Spray with "no treatment" instead of the SoC. One study 9 considered a societal perspective in their sensitivity analysis alongside a payer perspective.…”

“…Several sources were used to derive data regarding costing of resource use including from literature review (e.g. previous economic evaluations, resource utilization study) [9][10][11]16,17,[21][22][23] and Ex-factory price for drugs 9,20 . All studies clearly described the choice of outcomes and used QALY as the summary health outcome measure.…”